5 recruiting, 2 active not recruiting, 2 not yet recruiting, 1 completed. 10 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Recruiting 5, Active not recruiting 2, Not yet recruiting 2, Completed 1 |
| Phase 1 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Metabolic Dysfunction-associated Steatohepatitis (MASH): new trials by email Literature Review of Metabolic Dysfunction-associated Steatohepatitis (MASH) trials Research Report on Metabolic Dysfunction-associated Steatohepatitis (MASH)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Evaluate the Efficacy and Safety of QL2401 in Patients With Metabolic Dysfunction-associated Steatohepatitis and Liver Fibrosis QL2401 25 mg, QL2401 50 mg, QL2401 100 mg - Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 132 | 2026-12-01 | 2026-10-22 |
| A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated Steatohepatitis HRS-4729 Injection, HRS9531 Injection, HRS-4729 Injection Placebo - Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Phase 2 | Recruiting | Fujian Shengdi Pharmaceutical Co., Ltd. | 160 | 2026-08-14 | 2026-08-26 |
| A Study of VV-14303 for the Treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH) VV-14303 - Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 1 / Phase 2 | Recruiting | Kriya Therapeutics, Inc. | 56 | 2026-07-30 | 2026-09-01 |
| Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) ALN-CIDEB, Placebo - Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Phase 2 | Recruiting | Regeneron Pharmaceuticals | 150 | 2026-07-06 | 2026-10-26 |
| A Study of CS060380 Tablets in Patients With MASH and Obesity semaglutide, CS060380, Placebo - Metabolic Dysfunction-associated Steatohepatitis (MASH), Obesity | Phase 2 | Active not recruiting | Cascade Pharmaceuticals, Inc | 130 | 2026-04-02 | 2026-08-10 |
| A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) UBT251, Placebo - Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | Recruiting | The United Bio-Technology (Hengqin) Co., Ltd. | 156 | 2025-09-30 | 2026-11-03 |
| A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) Placebo, IBI362 - Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | Active not recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 181 | 2025-06-20 | 2026-10-20 |
| To Evaluate the Tolerability, Pharmacokinetics, and Pharmacodynamics of IMM-H014 in Patients With MASH IMM-H014, Placebo - Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Phase 1 / Phase 2 | Not yet recruiting | Changchun Intellicrown Pharmaceutical Co. LTD | 40 | 2025-06-10 | 2025-06-13 |
| A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH) Miricorilant (Cohort A), Placebo (Cohort A), Miricorilant (Cohort B) - Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | Completed | Corcept Therapeutics | 175 | 2023-10-25 | 2026-09-29 |
| A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition ALN-HSD, Placebo - Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | Phase 2 | Recruiting | Regeneron Pharmaceuticals | 120 | 2023-02-09 | 2026-10-08 |
Non-alcoholic Fatty Liver Disease (3) · Fibrosis (1) · Hepatitis (1) · Liver Cirrhosis (1) · Obesity (1)
Digestive System Diseases (3) · Fatty Liver (3) · Liver Diseases (3) · Pathological Conditions, Signs and Symptoms (2) · Body Weight (1) · Nutrition Disorders (1) · Nutritional and Metabolic Diseases (1) · Overnutrition (1) · Overweight (1) · Pathologic Processes (1) · Signs and Symptoms (1)
CORT118335 (1) · mazdutide (1) · semaglutide (1)
Regeneron Pharmaceuticals (2) · Cascade Pharmaceuticals, Inc (1) · Changchun Intellicrown Pharmaceutical Co. LTD (1) · Corcept Therapeutics (1) · Fujian Shengdi Pharmaceutical Co., Ltd. (1) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Kriya Therapeutics, Inc. (1) · Qilu Pharmaceutical Co., Ltd. (1) · The United Bio-Technology (Hengqin) Co., Ltd. (1)
China (5) · United States (4) · Puerto Rico (3) · India (1) · Japan (1) · New Zealand (1) · South Korea (1)
Kavita Juneja, MD (1) · Qinglong Jin (1) · Weiqing Wang, Ph.D. (1) · Yanhua Ding (1)